N-Isopropyl-neopentan-diamin | 90533-00-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Isopropyl-neopentan-diamin
• 英文别名: 2,2-dimethyl-N'-propan-2-ylpropane-1,3-diamine
• CAS: 90533-00-9
• 化学式: C₈H₂₀N₂
• 分子量: 144.26
• InChiKey: GDYLJJDISUQZJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(3-羟基亚胺-2,2,4,4-四甲基环丁基亚基)羟胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 N-Isopropyl-neopentan-diamin
  参考文献：
  名称：

  Anomalous Reduction of 2,2,4,4-Tetramethylcyclobutane-1,3-dioxime by Lithium Aluminum Hydride

  摘要：

  DOI：

  10.1021/jo01034a003

文献信息

• 2, 6-NAPHTHRIDINE DERIVATIVES
  申请人：van Eis Maurice

  公开号：US20100130469A1

  公开（公告）日：2010-05-27

  The present invention relates to novel organic compounds comprising a naphthyridine which may be mediators of a selective subset of kinases belonging to the AGC kinase family, such as for example PKC, PKD, PKN-1/2, CDK-9, MRCK-beat, PASK, PRKX, ROCK-I/II or mediators of other kinases, the selectivity of which would be depending on the structural variation thereof.

  本发明涉及一种新的有机化合物，包括一种萘啶，它可能是AGC激酶家族的一种选择性亚组的介质，例如PKC，PKD，PKN-1/2，CDK-9，MRCK-beat，PASK，PRKX，ROCK-I/II或其他激酶的介质，其选择性取决于其结构变化。
• Toll-like receptor antagonist compounds and methods of use
  申请人：Dynavax Technologies Corporation

  公开号：US11370794B2

  公开（公告）日：2022-06-28

  The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

  本发明涉及式 (I) 化合物： 或其盐或溶液，其中变量如本文所述。式（I）化合物及其药物组合物是类毒素受体如 TLR7、TLR8 和/或 TLR9 的拮抗剂。在某些实施方案中，本发明的化合物可用于抑制免疫反应和治疗与不良免疫反应相关的疾病。
• TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
  申请人：Dynavax Technologies Corporation

  公开号：US20190345161A1

  公开（公告）日：2019-11-14

  The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
• POLYMER-LIPIDS AND COMPOSITIONS
  申请人：Massachusetts Institute of Technology

  公开号：US20200172663A1

  公开（公告）日：2020-06-04

  The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.
• US7498405B2
  申请人：——

  公开号：US7498405B2

  公开（公告）日：2009-03-03